WO2004105703A3 - Compounds, formulations, and methods for treating or preventing rosacea - Google Patents

Compounds, formulations, and methods for treating or preventing rosacea Download PDF

Info

Publication number
WO2004105703A3
WO2004105703A3 PCT/US2004/016799 US2004016799W WO2004105703A3 WO 2004105703 A3 WO2004105703 A3 WO 2004105703A3 US 2004016799 W US2004016799 W US 2004016799W WO 2004105703 A3 WO2004105703 A3 WO 2004105703A3
Authority
WO
WIPO (PCT)
Prior art keywords
independently hydrogen
alkyl
compounds
alkoxy
methods
Prior art date
Application number
PCT/US2004/016799
Other languages
French (fr)
Other versions
WO2004105703A2 (en
Inventor
Jack Dejovin
Thomas M Rossi
Original Assignee
Sansrosa Pharmaceutical Dev In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33457481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004105703(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL04753601T priority Critical patent/PL1631293T5/en
Priority to AT04753601T priority patent/ATE530185T1/en
Priority to MXPA05014107A priority patent/MXPA05014107A/en
Priority to NZ544300A priority patent/NZ544300A/en
Priority to CN2004800217075A priority patent/CN1829518B/en
Priority to PL14179642T priority patent/PL2815748T3/en
Priority to EP04753601.6A priority patent/EP1631293B2/en
Priority to ES04753601.6T priority patent/ES2376172T5/en
Priority to DK04753601.6T priority patent/DK1631293T4/en
Priority to EP14179642.5A priority patent/EP2815748B1/en
Priority to CA2530938A priority patent/CA2530938C/en
Priority to SI200431808T priority patent/SI1631293T2/en
Priority to AU2004242967A priority patent/AU2004242967C1/en
Application filed by Sansrosa Pharmaceutical Dev In filed Critical Sansrosa Pharmaceutical Dev In
Publication of WO2004105703A2 publication Critical patent/WO2004105703A2/en
Publication of WO2004105703A3 publication Critical patent/WO2004105703A3/en
Priority to IL172612A priority patent/IL172612A/en
Priority to NO20056104A priority patent/NO333468B1/en
Priority to HK06105770.9A priority patent/HK1084591A1/en
Priority to LU92462C priority patent/LU92462I2/en
Priority to HUS1400029C priority patent/HUS1400029I1/en
Priority to CY2014028C priority patent/CY2014028I1/en
Priority to CY20201100775T priority patent/CY1123393T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: (I) wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.
PCT/US2004/016799 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea WO2004105703A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
AT04753601T ATE530185T1 (en) 2003-05-27 2004-05-26 COMPOUNDS, FORMULATIONS AND METHODS FOR TREATING OR PREVENTING ROSACEA
SI200431808T SI1631293T2 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea
CA2530938A CA2530938C (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea
NZ544300A NZ544300A (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea
CN2004800217075A CN1829518B (en) 2003-05-27 2004-05-26 Use of brimonidine in preparing medicine for treating or preventing rosacea and its symptom
PL14179642T PL2815748T3 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea
EP04753601.6A EP1631293B2 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea
ES04753601.6T ES2376172T5 (en) 2003-05-27 2004-05-26 Compounds, formulations and methods to treat or prevent rosacea
DK04753601.6T DK1631293T4 (en) 2003-05-27 2004-05-26 COMPOUNDS, FORMULATIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF rosacea
AU2004242967A AU2004242967C1 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea
MXPA05014107A MXPA05014107A (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea.
PL04753601T PL1631293T5 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea
EP14179642.5A EP2815748B1 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea
IL172612A IL172612A (en) 2003-05-27 2005-12-15 Formulations and uses thereof in the manufacture of medicaments for treating or preventing rosacea
NO20056104A NO333468B1 (en) 2003-05-27 2005-12-21 Use of a composition for treating or preventing rosacea as well as topical composition
HK06105770.9A HK1084591A1 (en) 2003-05-27 2006-05-18 Compounds, formulations, and methods for treating or preventing rosacea
LU92462C LU92462I2 (en) 2003-05-27 2014-05-28 BRIMONIDINE AND ITS PHARMACEUTICAL SALTS FOR USE AS A MEDICAMENT FOR THE TREATMENT OF ROSACEA-INDUCED REDNESS
HUS1400029C HUS1400029I1 (en) 2003-05-27 2014-06-02 Compounds, formulations, and methods for treating or preventing rosacea
CY2014028C CY2014028I1 (en) 2003-05-27 2014-07-31 COMPOUNDS, PHARMACEUTICAL FORMS AND METHODS FOR THE TREATMENT OR PREVENTION OF ACNE ROSEPHUM
CY20201100775T CY1123393T1 (en) 2003-05-27 2020-08-18 COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OR PREVENTION OF ACNE ROSE CHROMA

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47361103P 2003-05-27 2003-05-27
US60/473,611 2003-05-27
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
US10/853,585 2004-05-25

Publications (2)

Publication Number Publication Date
WO2004105703A2 WO2004105703A2 (en) 2004-12-09
WO2004105703A3 true WO2004105703A3 (en) 2005-03-17

Family

ID=33457481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016799 WO2004105703A2 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea

Country Status (22)

Country Link
US (13) US7439241B2 (en)
EP (3) EP2815748B1 (en)
CN (4) CN101816793B (en)
AT (1) ATE530185T1 (en)
AU (1) AU2004242967C1 (en)
CA (1) CA2530938C (en)
CY (3) CY1112242T1 (en)
DK (3) DK2388007T3 (en)
ES (3) ES2547336T3 (en)
HK (3) HK1084591A1 (en)
HR (1) HRP20150957T1 (en)
HU (3) HUE027616T2 (en)
IL (1) IL172612A (en)
LT (1) LT2815748T (en)
LU (1) LU92462I2 (en)
MX (1) MXPA05014107A (en)
NO (1) NO333468B1 (en)
NZ (1) NZ544300A (en)
PL (3) PL2388007T4 (en)
PT (3) PT2815748T (en)
SI (3) SI1631293T2 (en)
WO (1) WO2004105703A2 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PT1761266E (en) * 2004-05-25 2013-06-04 Galderma Pharma Sa Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US20080095735A1 (en) * 2005-01-31 2008-04-24 Kross Robert D Skin-Protective Polymer For Use In Teat Care Compositions
DE202005002183U1 (en) 2005-02-04 2005-04-14 Beiersdorf Ag Skin-soothing cream lotion
KR20080006568A (en) * 2005-03-30 2008-01-16 레반스 테라퓨틱스, 아이엔씨. Compositions and methods for treating acne
CN103948927B (en) 2005-06-17 2017-11-07 威斯康星校友研究基金会 The topical vasoconstrictor preparations and method of cell are protected in cancer chemotherapy and radiotherapy
WO2007002447A2 (en) * 2005-06-23 2007-01-04 Bioform Medical, Inc. Compositions for treating rosacea
FR2894474B1 (en) * 2005-12-12 2008-04-11 Galderma Res & Dev HYDRO-ALCOHOLIC DEPIGMENTING GEL
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
DK2182960T3 (en) * 2007-07-27 2014-05-26 Galderma Lab Inc Compounds, Formulations and Methods for Reducing Skin Wrinkles, Furrows and Slackness
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
JP5670196B2 (en) * 2007-11-16 2015-02-18 バイセプト セラピューティクス、インク． Compositions and methods for treating purpura
IE20070935A1 (en) * 2007-12-21 2009-06-24 Trinity College Dublin Guanidine based compounds and their use in the treatment of mental and neurological disorders.
CA2709199A1 (en) * 2007-12-21 2009-07-02 Galderma Laboratories, Inc. Pre-surgical treatment
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US8080550B2 (en) 2008-08-01 2011-12-20 Alpha Synergy Development, Inc. Anesthetic compositions and methods of use
WO2010085753A1 (en) * 2009-01-23 2010-07-29 Jr Chem, Llc Rosacea treatments and kits for performing them
FR2942138A1 (en) 2009-02-16 2010-08-20 Galderma Res & Dev ASSOCIATION OF COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DERMATOLOGICAL DISEASES
RU2572692C2 (en) * 2009-05-15 2016-01-20 Рекро Фарма, Инк. Dexmedetomidine sublingual compositions and methods of application thereof
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
CN104324378A (en) * 2009-05-29 2015-02-04 盖尔德马研究及发展公司 Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
JP2013508454A (en) * 2009-10-26 2013-03-07 ガルデルマ ファルマ ソシエテ アノニム Treatment or prevention of acute erythema
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
EP2552449B1 (en) * 2010-03-26 2017-04-19 Galderma Research & Development Compositions comprising brimonidine for the treatment of erythema
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
RU2587041C2 (en) * 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Method of preventing or treating skin tumour
US20130190317A1 (en) * 2010-08-06 2013-07-25 Galderma Research & Development Snc Combination of compounds for treating or preventing skin diseases
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
AU2011317642A1 (en) * 2010-10-21 2013-05-02 Galderma S.A. Topical gel composition
FR2966365B1 (en) * 2010-10-21 2012-11-09 Galderma Sa TOPICAL GEL COMPOSITION
FR2966366B1 (en) * 2010-10-21 2012-11-09 Galderma Sa BRIMONIDINE GEL COMPOSITION
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
AR083651A1 (en) * 2010-10-21 2013-03-13 Galderma Sa BRIMONIDINE COMPOSITIONS IN GEL AND METHODS OF USE
CA2818144C (en) * 2010-11-16 2020-09-22 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8883838B2 (en) * 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
WO2012087280A2 (en) 2010-12-20 2012-06-28 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
WO2012083397A1 (en) 2010-12-22 2012-06-28 Silvestre Labs Químia E Farmaceutica Ltda. Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
US20120208858A1 (en) * 2011-02-15 2012-08-16 Allergan, Inc. Pharmaceutical Cream Compositions of Oxymetazoline and Methods of Use
CN102260608B (en) * 2011-06-23 2012-07-04 江苏安惠生物科技有限公司 Lucid ganoderma soap and preparation method thereof
CA2841632A1 (en) * 2011-07-14 2013-01-17 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
CA2850964C (en) 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
CN103889416A (en) 2011-10-19 2014-06-25 高德美国际公司 Method for treating capillary hemangiomas
RU2014119879A (en) 2011-10-19 2015-11-27 Галдерма С.А. METHOD FOR REDUCING BLOOD TIDGE TO FACE WITH SYSTEMATIC USE OF PHOSPHODESTERASE TYPE 5 INHIBITORS
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (en) * 2011-11-10 2015-08-10 TREATMENT OF SKIN DISEASES AND STATES
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
RU2692245C2 (en) 2011-12-11 2019-06-24 Рекро Фарма, Инк. Intranasal dexmedetomidine compositions and methods of use thereof
CA2863760A1 (en) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
FR3000398A1 (en) * 2012-12-31 2014-07-04 Galderma Res & Dev COMBINATION OF LAROPIPRANT AND BRIMONIDINE FOR THE TREATMENT OF ROSACEA
FR3000397A1 (en) 2012-12-31 2014-07-04 Galderma Res & Dev COMBINATION OF LAROPIPRANT AND IVERMECTIN FOR THE TREATMENT OF ROSACEA
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
KR20150098675A (en) * 2012-12-24 2015-08-28 라모트 앳 텔-아비브 유니버시티 리미티드 Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
US9861645B2 (en) 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations
BR112015027984A2 (en) 2013-05-06 2017-09-05 Allergan Inc ALPHA-ADRENERGIC AGONISTS FOR THE TREATMENT OF TISSUE DAMAGE
WO2015013709A2 (en) * 2013-07-26 2015-01-29 Galderma Research & Development Method for treating skin thickening
RU2648449C2 (en) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
WO2015054059A2 (en) 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
KR101948779B1 (en) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 Dexmedetomidine transdermal delivery devices and methods for using the same
FR3015288B1 (en) 2013-12-19 2016-02-12 Galderma Res & Dev USE OF NARATRIPTAN IN THE TREATMENT OF ROSACEA
AU2015274532B2 (en) * 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
US20150374686A1 (en) 2014-06-30 2015-12-31 Galderma S.A. Methods of Treating Flushing Associated with Carcinoid Tumors and Carcinoid Syndrome
RU2560698C1 (en) * 2014-08-15 2015-08-20 Общество с ограниченной ответственностью "Уральский медико-химический центр" (ООО "УМХЦ") Topical agent for acne
US9351945B1 (en) * 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
US9937117B2 (en) 2015-07-09 2018-04-10 Galderma S.A. Method of reducing hair loss associated with chemotherapy
FR3041537B1 (en) * 2015-09-29 2018-11-30 Galderma Research & Development BRIMONIDINE CONTAINING CHEMICAL FOAM WITHOUT RINSE AND USE THEREOF FOR TREATING ROSACEA.
US11213539B2 (en) 2015-11-17 2022-01-04 Galderma Holding SA Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
US10617688B2 (en) 2016-03-22 2020-04-14 Doris Maria HEXSEL Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas
US10744135B2 (en) * 2016-06-28 2020-08-18 Doris Maria HEXSEL Use of an active substance in the treatment of melasma
CN109265448B (en) * 2018-11-15 2020-09-15 三峡大学 Tert-butyl-containing N-imidazole acetyl dihydroquinoxaline derivative, synthesis method and application thereof as bactericide
WO2020170034A1 (en) 2019-02-19 2020-08-27 Sol-Gel Technologies Ltd. Method for long-term treatment of rosacea
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
CN113784712A (en) 2019-05-01 2021-12-10 克雷西奥生物科技有限公司 Method for treating pruritus
AU2021334325A1 (en) * 2020-08-26 2023-03-02 Oticara, Inc. Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation
RU2766973C1 (en) * 2021-10-05 2022-03-16 Татьяна Сергеевна Русина Method for combination therapy for rosacea of erithematous-teleangectatic subtype
WO2023130086A1 (en) * 2021-12-31 2023-07-06 Jss Research, Llc Compositions and methods for topical treatment of vascular conditions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US5442053A (en) * 1982-09-28 1995-08-15 Fidia, S.P.A. Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US3560501A (en) 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
BG16042A3 (en) 1968-11-12 1972-05-20 Nans Ott METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES
US3594380A (en) 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (en) 1971-04-21 1971-09-16 Labofina Sa NEW POLYMERS CONTAINING PYRAZOLE UNITS AND PROCESS FOR PREPARING THESE POLYMERS.
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (en) 1972-02-29 1973-08-27 Pfizer NEW DERIVATIVES OF QUINOLEINE, QUINOXALINE AND QUINAZOLINE ER PHARMACEUTICAL COMPOSITION CONTAINING THEM
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
DE2924005C2 (en) * 1979-06-13 1984-07-05 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Agent containing isosorbide dinitrate
US4908387A (en) 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5077292A (en) 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5204347A (en) 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5198442A (en) 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5326763A (en) 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5130441A (en) 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5237072A (en) 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
IT1248014B (en) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa PROTRACTED OPHTHALMIC PREPARATIONS
US5292517A (en) * 1992-02-25 1994-03-08 Allergan, Inc. pH sensitive, reversible gelling, copolymeric erodible drug delivery system
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
AU688380B2 (en) 1993-10-13 1998-03-12 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6117871A (en) 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
WO1996013267A2 (en) 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US5693646A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US5620416A (en) * 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US5753637A (en) 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US5910312A (en) 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
JP2001512471A (en) 1997-02-21 2001-08-21 バイヤースドルフ・アクチエンゲゼルシヤフト Preparations for the treatment of rosacea
NZ500712A (en) * 1997-04-10 2002-10-25 Agennix Inc Use of a lactoferin product to inhibit the inflammatory activity of interleukin-1 beta in the treatment of allergen-induced inflammatory disorders
JPH1129482A (en) 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd Pharmaceutical composition
US6513247B1 (en) * 1997-05-29 2003-02-04 Ariel Krasik-Geiger Calibrated angle and depth scissors
US6159944A (en) 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
AR020660A1 (en) 1998-09-30 2002-05-22 Alcon Lab Inc ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF EYES, EARS AND NOSE
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
IN185228B (en) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
WO2000076502A1 (en) 1999-06-11 2000-12-21 The Ohio State University Research Foundation Methods and compositions for treating raynaud's phenomenon and scleroderma
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6147102A (en) 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
DK1252157T3 (en) * 2000-01-31 2004-10-25 Pfizer Prod Inc Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
NZ521185A (en) 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
WO2002036144A1 (en) 2000-10-30 2002-05-10 University Of Zurich Gnrh analogues for treatment of urinary incontinence
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
WO2002089743A2 (en) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
TNSN02063A1 (en) * 2001-07-07 2005-12-23 Egyptian Natural Oil Co Natoil The medical effect of jojoba oil
US7115724B2 (en) * 2001-08-22 2006-10-03 Wyeth Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor
US7704530B2 (en) 2001-09-14 2010-04-27 Kenji Nakamura Antimicrobially treated material and methods of preventing coloring thereof
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040092482A1 (en) 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
WO2004103233A1 (en) 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
FR2862537B1 (en) * 2003-11-21 2006-03-03 Galderma Res & Dev USE OF FEPRADINOL FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ROSACEA
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PT1761266E (en) * 2004-05-25 2013-06-04 Galderma Pharma Sa Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
WO2007095670A1 (en) * 2006-02-20 2007-08-30 Commonwealth Scientific And Industrial Research Organisation Method and composition for priming wood and natural fibres
WO2008140781A1 (en) * 2007-05-09 2008-11-20 Atherogenics, Inc. Spiro compounds for treatment of inflammatory disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
EP2552449B1 (en) * 2010-03-26 2017-04-19 Galderma Research & Development Compositions comprising brimonidine for the treatment of erythema
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US5442053A (en) * 1982-09-28 1995-08-15 Fidia, S.P.A. Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy

Also Published As

Publication number Publication date
PT2815748T (en) 2020-08-31
ATE530185T1 (en) 2011-11-15
US20060171974A1 (en) 2006-08-03
CN102743380A (en) 2012-10-24
PL2388007T3 (en) 2016-01-29
EP2815748B1 (en) 2020-08-05
HRP20150957T1 (en) 2015-11-20
ES2547336T3 (en) 2015-10-05
IL172612A (en) 2013-03-24
US20100227867A1 (en) 2010-09-09
EP2388007A1 (en) 2011-11-23
PL1631293T3 (en) 2012-03-30
AU2004242967B2 (en) 2009-05-28
US20050276830A1 (en) 2005-12-15
US20160220565A1 (en) 2016-08-04
EP1631293A2 (en) 2006-03-08
CY1123393T1 (en) 2021-12-31
SI2388007T1 (en) 2016-01-29
US20060264515A1 (en) 2006-11-23
CA2530938A1 (en) 2004-12-09
DK1631293T4 (en) 2015-01-12
US8426410B2 (en) 2013-04-23
HK1204996A1 (en) 2015-12-11
SI2815748T1 (en) 2020-11-30
US7838563B2 (en) 2010-11-23
PL1631293T5 (en) 2015-04-30
CN102743380B (en) 2015-08-12
HK1164126A1 (en) 2012-09-21
CA2530938C (en) 2011-12-13
CY2014028I2 (en) 2015-12-09
AU2004242967A1 (en) 2004-12-09
CN101380321A (en) 2009-03-11
EP1631293A4 (en) 2009-05-06
PT2388007E (en) 2015-10-14
US20130172358A1 (en) 2013-07-04
DK1631293T3 (en) 2012-02-13
CY1112242T1 (en) 2015-12-09
HUS1400029I1 (en) 2017-10-30
CN101816793A (en) 2010-09-01
WO2004105703A2 (en) 2004-12-09
CN1829518B (en) 2010-09-08
EP1631293B1 (en) 2011-10-26
SI1631293T2 (en) 2015-02-27
HK1084591A1 (en) 2006-08-04
DK2388007T3 (en) 2015-09-28
LU92462I2 (en) 2015-11-02
US8557817B2 (en) 2013-10-15
DK2815748T3 (en) 2020-08-24
EP2388007B1 (en) 2015-06-24
EP1631293B2 (en) 2014-10-08
HUE027616T2 (en) 2016-11-28
ES2812532T3 (en) 2021-03-17
AU2004242967C1 (en) 2015-12-24
US8231885B2 (en) 2012-07-31
MXPA05014107A (en) 2006-03-17
US8859551B2 (en) 2014-10-14
SI1631293T1 (en) 2012-02-29
NZ544300A (en) 2009-03-31
US20150202202A1 (en) 2015-07-23
ES2376172T5 (en) 2015-01-08
NO333468B1 (en) 2013-06-17
US20100021402A1 (en) 2010-01-28
US20170216282A1 (en) 2017-08-03
EP2815748A1 (en) 2014-12-24
LT2815748T (en) 2020-11-25
US8993571B2 (en) 2015-03-31
US7439241B2 (en) 2008-10-21
PL2388007T4 (en) 2016-03-31
CN101816793B (en) 2012-08-15
NO20056104L (en) 2006-02-03
US20100130502A1 (en) 2010-05-27
CN101380321B (en) 2013-03-27
PL2815748T3 (en) 2020-11-16
HUE051833T2 (en) 2021-03-29
PT1631293E (en) 2012-02-01
CN1829518A (en) 2006-09-06
US20040242588A1 (en) 2004-12-02
CY2014028I1 (en) 2015-12-09
US20120277241A1 (en) 2012-11-01
US20130172359A1 (en) 2013-07-04
ES2376172T3 (en) 2012-03-09

Similar Documents

Publication Publication Date Title
WO2004105703A3 (en) Compounds, formulations, and methods for treating or preventing rosacea
WO2005115395A3 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
WO2009032773A3 (en) Compositions and methods for treating demodex infestations
WO2007109230A3 (en) Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
WO2008130953A3 (en) 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2008079339A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2007053844A8 (en) Compositions and methods for treating inflammatory disorders
EP1508570A4 (en) Novel physiolgically active substances
WO2005082350A8 (en) Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation
IL178563A0 (en) Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity
NO20045556L (en) Compound to abrogate DNA damage induced cell cycle G2 checkpoint and / or enhance anti-cancer activity in DNA damaging treatments
CY1116690T1 (en) LOCAL COMPOSITION FOR USE IN RED TREATMENT ACADEMY
ATE437881T1 (en) POLYETHER BREVETOXINE DERIVATIVES AS A TREATMENT FOR CYSTIC FIBROSIS, MUCOCILIAR DYSFUNCTION AND LUNG DISEASES
WO2006015183A3 (en) Pharmaceutical compositions for treating disorders of the skin
HK1089361A1 (en) Topical administration of vasoactive vitamin b3 compounds for promoting sleep
Bhattacharya Comparison of Different Lattice Models of Amphiphiles: A Monte Carlo Study.
UA85239C2 (en) Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480021707.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172612

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004753601

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/014107

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 544300

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2530938

Country of ref document: CA

Ref document number: 2004242967

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2738/KOLNP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004242967

Country of ref document: AU

Date of ref document: 20040526

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004242967

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004753601

Country of ref document: EP